Researcher

Rong En Tay is a Group Leader at the A*STAR Singapore Immunology Network (A*STAR SIgN). Tay completed his PhD training at Harvard University in 2019, where he designed and executed functional screens in primary CD8 T cells using small molecule inhibitors and CRISPR-Cas9 gene editing. Using these approaches, he discovered novel roles for epigenetic regulators, leading to proof-of-concept studies for potential development of therapeutics. Upon returning to A*STAR SIgN, he applied his expertise in building functional screening platforms to target discovery for liver cancer immunotherapy, working in close collaboration with the National Cancer Centre. Tay became a Group Leader in 2023.

For his work on discovering and validating novel targets for HCC immunotherapy, Tay was awarded two Young Individual Researcher Grants from the National Medical Research Council and two pre-pilot awards from the Singapore Therapeutics Development Review.